T2 Biosystems to Report Fourth Quarter and Full Year 2022 Financial Results on March 13, 2023
T2 Biosystems (NASDAQ:TTOO) will announce its financial results for Q4 and full year 2022 on March 13, 2023, after market close. A conference call will follow at 4:30 p.m. ET, allowing investors to access the details via a live and archived webcast. The company specializes in the rapid detection of sepsis-causing pathogens and antibiotic resistance genes, emphasizing its commitment to enhancing patient care. T2 Biosystems' products include innovative testing panels, powered by proprietary T2 Magnetic Resonance technology, aimed at improving treatment speed and reducing costs.
- None.
- None.
LEXINGTON, Mass., March 03, 2023 (GLOBE NEWSWIRE) -- T2 Biosystems, Inc. (NASDAQ:TTOO), a leader in the rapid detection of sepsis-causing pathogens and antibiotic resistance genes, announced today that it will report financial results for the fourth quarter and full year 2022 after market close on Monday, March 13, 2023. Company management will host a corresponding conference call beginning at 4:30 p.m. Eastern Time.
Investors interested in listening to the conference call may do so by accessing a live and archived webcast of the event at www.t2biosystems.com, on the Investors page in the Events & Presentations section. To listen to the conference call, please dial 1-877-545-0523 (US/Canada) or 1-973-528-0016 (International), passcode 411579, approximately ten to five minutes prior to the start time.
About T2 Biosystems:
T2 Biosystems, a leader in the rapid detection of sepsis-causing pathogens and antibiotic resistance genes, is dedicated to improving patient care and reducing the cost of care by helping clinicians effectively treat patients faster than ever before. T2 Biosystems’ products include the T2Dx® Instrument, T2Bacteria® Panel, T2Candida® Panel, T2Resistance® Panel, and T2SARS-CoV-2™ Panel and are powered by the Company’s proprietary T2 Magnetic Resonance (T2MR®) technology. T2 Biosystems has an active pipeline of future products, including the T2Biothreat Panel, T2Cauris™ Panel, T2Lyme™ Panel, as well as additional products for the detection of bacterial and fungal pathogens and associated antimicrobial resistance markers. For more information, please visit www.t2biosystems.com.
Investor Contact:
Philip Trip Taylor, Gilmartin Group
ir@T2Biosystems.com
415-937-5406
FAQ
When will T2 Biosystems release its Q4 2022 financial results?
What time is the T2 Biosystems conference call on March 13, 2023?
How can I access the T2 Biosystems conference call?
What are the main products of T2 Biosystems?
What technology powers T2 Biosystems' products?
